INVO Bioscience Updates Merger Plans with NAYA Biosciences
INVO Bioscience Extends Merger Agreement with NAYA
INVO Bioscience, Inc. (NASDAQ: INVO), a progressive player in the medical device sector, has announced a significant development regarding its merger with NAYA Biosciences, Inc. Following constructive negotiations, the parties have agreed to amend the merger agreement, extending the deadline for completion to October 14, 2024. This extension is intended to ensure alignment with Nasdaq's listing requirements and address previous contractual concerns.
Details of the Amended Agreement
Located in Sarasota, Florida, INVO Bioscience has consented to the purchase of 27,500 shares of its Series A Preferred Stock by NAYA for a sum of $137,500. This maneuver forms part of a wider arrangement, allowing NAYA to potentially acquire an additional 72,500 shares, totaling $362,500, contingent on the merger's ultimate realization.
Structure of the Merger Consideration
According to the revised agreement, the merger will involve a combination of INVO's common stock and a newly established Series C Convertible Preferred Stock. Importantly, the issuance of common stock will not exceed 19.9% of INVO's outstanding shares just prior to the merger, with any remaining balance compensated through Series C Preferred Stock. Furthermore, it has been noted that NAYA will likely transfer a majority of the common stock shares to its secured lender, Five Narrow Lane LP, after the merger transaction.
Shareholder Approval and Stock Meeting Plans
INVO Bioscience is committed to seeking shareholder consent for the issuance of common stock upon conversion of the Series C Preferred Stock. Plans to convene a stockholder meeting will occur within 120 days post-merger, contingent on any delays provoked by SEC feedback on the proxy statement. Once shareholder permission is obtained, the Series C Preferred Stock will automatically convert into common stock, representing around 60.1% of INVO's overall common stock.
Regulatory and Closing Conditions
The culmination of the merger is subject to conventional closing standards, including regulatory approvals. Additionally, the agreement upholds other customary closing prerequisites. This announcement was made to enlighten shareholders and the market about factual details surrounding the ongoing merger process.
Recent Developments at INVO Bioscience
In other noteworthy developments, INVO Bioscience has successfully received an extension from The Nasdaq Stock Market, allowing it to regain compliance with listing requisites. This decision followed a session with the Nasdaq Hearing Panel, which authorized additional time for the company to meet necessary standards to avoid potential delisting linked to inadequate stockholders' equity.
Ensuring Compliance with Nasdaq Requirements
As part of its strategic plan, INVO Bioscience sought and received an extension until October 14, 2024, to complete its acquisition of NAYA Biosciences, Inc., with the Nasdaq Panel accepting this request for continued listing contingent upon ongoing adherence to Nasdaq's Listing Rule 5505.
Ownership Changes in Subsidiary
In parallel, Wood Violet Fertility, LLC, which operates as a subsidiary of INVO Bioscience, has transferred ownership of Wisconsin Fertility and Reproductive Surgery Associates, S.C. to Dr. Donna Baldwin. This transition marked the end of employment for Dr. Elizabeth Pritts, the previous owner, officer, and director pertaining to the entity.
Frequently Asked Questions
What recent developments have occurred with INVO Bioscience?
INVO Bioscience has extended its merger agreement with NAYA Biosciences, giving both parties until October 14, 2024, to finalize the merger.
How will the merger affect INVO's stock structure?
The merger will involve common stock and a new Series C Convertible Preferred Stock, with specific limits on common stock issuance to ensure balance.
What approvals are necessary for the merger completion?
The merger completion is subject to customary regulatory approvals and closing conditions that must be satisfied.
How is INVO Bioscience ensuring compliance with Nasdaq?
INVO has obtained an extension from Nasdaq, allowing it additional time to meet listing requirements following potential delisting concerns.
What recent ownership change occurred in INVO's subsidiary?
Wood Violet Fertility, LLC transferred ownership of Wisconsin Fertility and Reproductive Surgery Associates to Dr. Donna Baldwin, resulting in a change in management.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Port Houston Advances Major Project 11 with Milestones Achieved
- Source Agriculture Partners with RWE Clean Energy for Wind Project
- Oracle Corp Successfully Raises $6.25 Billion with New Notes
- Tellurian Inc. Moves Forward with Woodside Energy Merger Strategy
- AT&T's Recent Dividend Strategy: Key Insights and Updates
- Ensysce Biosciences: Navigating Compliance Challenges and Growth
- Playa Hotels & Resorts Secures Future with Executive Agreements
- Tesla Gears Up for an Exciting October with Key Events Ahead
- Cohen & Steers Fund Updates Distribution Sources for Shareholders
- Jacobs Completes Spin-off and Merger, Focuses on Growth
Recent Articles
- Transforming Bottling Lines: The Future of Machinery Growth
- Bark Inc. Achieves Major Shareholder Milestones for Growth
- AI Transforming Interactive Kiosk Market Growth Projections
- CSX Corp Strengthens Financial Framework with $550M Note Issuance
- Phinia Inc. Secures $450 Million in Senior Notes Offering
- Dorman Products Executive Sells Substantial Stock Holdings
- Recent Stock Transactions by Blackbaud's EVP Raise Interest
- Insights into Blackbaud's Recent Stock Sale and Performance
- Blackstone Mortgage Trust CFO Sells Shares, Impacts Outlook
- Klaviyo President Engages in Strategic Stock Sale and Insights
- Essex Property Trust EVP's Significant Stock Transaction Insights
- Arista Networks: Insider Trading Insights and Strong Growth
- Recent Stock Activity by Essex Property Trust's CEO Explained
- Klaviyo's CTO Allen Chaves Completes Notable Stock Sales
- Northern Trust Adjusts Prime Rate to Enhance Financial Services
- U.S. Bancorp Lowers Prime Lending Rate to 8% for Customers
- Arctaris Impact Investors Fuels Growth for Baltimore Firm
- Leadership Transition at Minsud Resources Corporation
- Silver Mountain Resources Implements Share Compensation for Directors
- XPEL Investors Face Securities Class Action Opportunity
- Investors Explore Legal Action Against Methode Electronics, Inc.
- Exciting Growth Expected in Smart Glasses Market Ahead
- Ethyl Alcohol Market Poised for Growth Amid AI Innovations
- Investors May Find Opportunities in Methode Electronics Case
- How Inspection Robots Are Transforming Industries with AI
- Automotive Touch Screen Control Systems Poised for Growth
- Incyte's Niktimvo Receives FDA Approval for Chronic GVHD Therapy
- AI Innovating Corporate Training Landscape with USD 60.4B Surge
- Northrop Grumman's B-21 Raider Flight Tests Surpass Expectations
- Transformative Developments in the Axial Spondyloarthritis Market
- Northrop Grumman's B-21 Raider Making Strides in Development
- Emerging Trends and Growth in the Laser Printer Market
- Five Below's Leadership Change: Preparing for a Bright Future
- Technavio Predicts Major Growth for Digital Video Content Market
- Jacobs Solutions Announces Upcoming Spin-Off and Updates
- Federal Reserve Initiates Significant Rate-Cutting Cycle
- Jerome Powell Discusses Potential Fed Rate Cuts This Year
- Taylor Morrison Home Corp: Recent Insider Activity & Growth
- CEO Michael Hartnett Makes Major Stock Moves at RBC Bearings
- Colombia's Stock Market Experiences Minor Declines Today
- Declining Trends in Russian Stocks: Market Analysis and Insights
- William Zerella's Stock Sale: Insights into ACV Auctions' Performance
- Understanding Insider Sales at PennyMac Financial Services
- Nicole Sherman Boosts Confidence in Riverview Bancorp with Stock Buy
- SES AI Corp's CFO Engages in $56K Stock Trading Activity
- Forge Global Shares Movement: Recent COO Sales and Market Outlook
- Stellantis N.V. Class Action Alert: Investors Empowered to Act
- C3 Pharmaceuticals Eyes IPO and Innovative Cannabis Tablet
- Cytek Biosciences Shines with Full Spectrum Technology Advances
- Aligos Therapeutics Set to Reveal Phase 2a Study Results Soon